Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Схожие документы

• Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
  по: Kanda, Tatsuo, et al.
  Опубликовано: (2016)
• Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
  по: Kanda, Tatsuo, et al.
  Опубликовано: (2017)
• Sofosbuvir treatment and hepatitis C virus infection
  по: Nakamura, Masato, et al.
  Опубликовано: (2016)
• Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
  по: Kanda, Tatsuo, et al.
  Опубликовано: (2016)
• Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
  по: Kanda, Tatsuo, et al.
  Опубликовано: (2015)